Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting

February 24, 2026

View Press Release Corporate presentation Contact us
Previous